Powder: -20°C for 3 years | In solvent: -80°C for 1 year
BP-5-087 is a STAT3 inhibitor, combining with BCR-ABL1 inhibition to overcome kinase-independent resistance in chronic myeloid leukemia.
パッケージサイズ | 在庫状況 | 単価(税別) |
---|---|---|
25 mg | 約6-8 週間 | ¥ 383,500 |
50 mg | 約6-8 週間 | ¥ 500,500 |
100 mg | 約6-8 週間 | ¥ 643,000 |
説明 | BP-5-087 is a STAT3 inhibitor, combining with BCR-ABL1 inhibition to overcome kinase-independent resistance in chronic myeloid leukemia. |
分子量 | 770.69 |
分子式 | C36H30F8N2O6S |
CAS No. | 1803281-30-2 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
You can also refer to dose conversion for different animals. 詳細
bottom
Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc.
BP-5-087 1803281-30-2 CP690550 CP-690550 HCl tasocitinib. Trade name Xeljanz. Tofacitinib CP 690550 CP-690550 Tofacitinib hydrochloride Inhibitor inhibitor inhibit